Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sen. Gorton Sets April Deadline For Alternatives To International Pricing Bill

Executive Summary

Sen. Gorton (R-Wash.) is asking the pharmaceutical industry to come up with a proposal before the April 17 Easter recess to address the international disparity in pharmaceutical prices.

You may also be interested in...



Medco/Washington Rx Plan Offers Mail Discounts Up To 49%, 30% At Retail

Merck-Medco will provide seniors in Washington state with discounts of up to 49% on mail-order prescription drug purchases through a new program initiated in conjunction with the governor's office.

Medco/Washington Rx Plan Offers Mail Discounts Up To 49%, 30% At Retail

Merck-Medco will provide seniors in Washington state with discounts of up to 49% on mail-order prescription drug purchases through a new program initiated in conjunction with the governor's office.

Pharmachemie tamoxifen

Teva subsidiary receives full approval for generic tamoxifen 10 mg tablet May 31. AstraZeneca still has patent protection on the compound (Nolvadex) until Aug. 20, 2002, and litigation is pending. The approval reflects an April Washington, D.C. federal court decision vacating FDA's award of 180 days of generic exclusivity to Barr, which has marketed tamoxifen under a patent settlement with AstraZeneca since 1992 (1"The Pink Sheet" April 10, p. 3)

Related Content

UsernamePublicRestriction

Register

SC143162

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel